1
|
Ang J, Shah R, Everard M, Keyzor C, Coombes I, Jenkins A, Thomas K, A'Hern R, Jones R, Blake P, Gabra H, Hall G, Gore M, Kaye S. A feasibility study of sequential doublet chemotherapy comprising carboplatin–doxorubicin and carboplatin–paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Ann Oncol 2009; 20:1787-93. [DOI: 10.1093/annonc/mdp193] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Montes A, Sandhu SK, Rothermundt C, Coombes I, A'Hern R, Keyzor C, Thomas A, Kaye S, Gore M. Phase I feasibility study of carboplatin plus capecitabine followed by maintenance capecitabine in patients (pts) with recurrent platinum-sensitive epithelial ovarian cancer (EOC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5564 Background: In a previous study, we noted a response rate (RR) of 61% for the 3 drug combination of carboplatin, epirubicin and capecitabine in platinum-sensitive recurrent EOC. This combination however resulted in excessive grade (G) 3–4 haematological toxicity (55%) (BJC 2006; 94:74). The current trial therefore assessed the feasibility and efficacy of the 2 drugs, carboplatin and capecitabine as second- or third-line treatment. Methods: Pts were administered carboplatin (AUC5) day 1 and capecitabine at a starting dose of 750 mg/m2 bd, days 1–21, q21 (dose level 1). The capecitabine dose was deescalated to 625 mg/m2 (dose level -1) and 500 mg/m2 (dose level -2) according to toxicity. Pts with an objective response or stable disease received maintenance capecitabine (at the same dose level) for up to 12 months or until progression. Responses were assessed with RECIST criteria and CA-125. Results: 19 of the 20 pts enrolled were evaluable for toxicity and response. Dose-limiting toxicity was observed at dose level 1 (G3 fatigue, G3 diarrhoea, G3 neutropenia of > 14 days; n = 3/5), dose level -1 (G3 angina (n = 2), G3 vomiting, G3 palmar plantar erythema; n = 4/7) and dose level-2 (diarrhoea / fatigue; n = 1/7). One patient had a G3 carboplatin hypersensivity reaction. 8 pts received maintenance capecitabine which was well tolerated. The overall RR was 53% with 10 partial responses and 5 stable diseases. The median progression free survival (PFS) was 6.5 months (m) and the 6mPFS was 63% with 2 pts currently ongoing treatment. The median PFS on maintenance was 3.2 m. Conclusions: The combination was well tolerated at the recommended phase II dose of carboplatin (AUC 5) and capecitabine (500 mg/m2 bd) with partial responses in over half of the cases. [Table: see text]
Collapse
Affiliation(s)
- A. Montes
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - S. K. Sandhu
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - C. Rothermundt
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - I. Coombes
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - R. A'Hern
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - C. Keyzor
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - A. Thomas
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - S. Kaye
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - M. Gore
- Guy's and St Thomas’ Hospital, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| |
Collapse
|
3
|
Rothermundt C, Hubner R, Ahmad T, Gibbens I, Keyzor C, Habeshaw T, Kaye S, Gore M. Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. Br J Cancer 2006; 94:74-8. [PMID: 16306873 PMCID: PMC2361084 DOI: 10.1038/sj.bjc.6602879] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Platinum-based combination chemotherapy has been proven to be superior to single-agent platinum in the treatment of relapsed ovarian cancer after a treatment-free interval of more than 6 months. A response rate of 41% was previously reported by our group using a combination of epirubicin, cisplatin and 5-FU in patients who relapsed within 12 months, we therefore assessed a similar, but more convenient combination of epirubicin, carboplatin and capecitabine in this phase-I/II trial. In total, 18 patients with recurrent epithelial ovarian carcinoma, who had not received more than two lines of chemotherapy and the treatment-free interval exceeded 6 months were treated with carboplatin AUC5, epirubicin 50 mg m(-2) and capecitabine at several dose levels on continuous 21 day cycles and 14 of 21 day cycles. Patients were assessed for toxicity and by CT and CA-125 for response. The overall response rate was 61.1%, with three complete and eight partial responses. Grade 3/4 haematological toxicity was seen in 10 out of 18 patients and caused dose reductions and treatment delays. The combination of epirubicin, carboplatin and capecitabine showed good activity but caused excessive toxicity. A phase-II trial using carboplatin and capecitabine is underway.
Collapse
Affiliation(s)
- C Rothermundt
- The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Gore M, Kaye S, Oza A, Keyzor C, Pyle L, Pereno R, Sklenar I, Zaknoen S, Johri A. Phase I trial of patupilone plus carboplatin in patients with advanced cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5087] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Gore
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - S. Kaye
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - A. Oza
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - C. Keyzor
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - L. Pyle
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - R. Pereno
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - I. Sklenar
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - S. Zaknoen
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| | - A. Johri
- Royal Marsden Hosp, London, United Kingdom; Royal Marsden Hosp, Surrey, United Kingdom; Princess Margaret Hosp, Toronto, ON, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corp, East Hanover, NJ
| |
Collapse
|
5
|
Shah RNH, Everard M, Keyzor C, Hall K, A’Hern R, Blake P, Gore ME, Kaye SB. A sequential doublet chemotherapy regimen in patients (pts) with advanced endometrial adenocarcinoma (EC) and gynecological mixed müllerian tumors (MMT). Maintaining activity with tolerability? J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - M. Everard
- Royal Marsden Hosp, Sutton, United Kingdom
| | - C. Keyzor
- Royal Marsden Hosp, Sutton, United Kingdom
| | - K. Hall
- Royal Marsden Hosp, Sutton, United Kingdom
| | - R. A’Hern
- Royal Marsden Hosp, Sutton, United Kingdom
| | - P. Blake
- Royal Marsden Hosp, Sutton, United Kingdom
| | - M. E. Gore
- Royal Marsden Hosp, Sutton, United Kingdom
| | - S. B. Kaye
- Royal Marsden Hosp, Sutton, United Kingdom
| |
Collapse
|
6
|
Hubner R, Ahmad T, Rigg A, Kaye S, Gibbens I, Keyzor C, Prouse A, Gore M. Epirubicin-carboplatin-capecitabine (ECarboX) in relapsed ovarian cancer: A phase I/II trial. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Hubner
- Royal Marsden Hospital, London, United Kingdom
| | - T. Ahmad
- Royal Marsden Hospital, London, United Kingdom
| | - A. Rigg
- Royal Marsden Hospital, London, United Kingdom
| | - S. Kaye
- Royal Marsden Hospital, London, United Kingdom
| | - I. Gibbens
- Royal Marsden Hospital, London, United Kingdom
| | - C. Keyzor
- Royal Marsden Hospital, London, United Kingdom
| | - A. Prouse
- Royal Marsden Hospital, London, United Kingdom
| | - M. Gore
- Royal Marsden Hospital, London, United Kingdom
| |
Collapse
|